Infection; Dialysis Catheter Clinical Trial
Official title:
Phase II Trial of a Novel Catheter Lock Solution For Adjunctive Treatment of Hemodialysis Catheter-Associated Bacteremia.
Aim: To conduct a randomized, double-blinded, controlled phase II trial to investigate the
use of a catheter lock solution consisting of N-acetylcysteine, tigecycline and heparin, in
addition to systemic antibiotics, for the treatment of hemodialysis catheter-associated
bacteremia via a catheter-salvage strategy.
The investigators plan to randomize 102 patients with hemodialysis catheter-associated
bacteremia to one of two treatment arms. All patients will receive systemic antibiotics for
treatment of their infection. Additionally, patients randomized to the interventional arm
will also receive a catheter lock solution consisting of N-acetylcysteine, tigecycline and
heparin for 2 weeks with the aim of salvaging the catheter. The control arm will receive only
an anticoagulant solution as a catheter lock which is standard of care - this can be either
heparin or citrate (depending on what agent is standard of care for a particular patient).
The main outcome of interest is successful treatment which is defined as a resolution of the
current episode of bacteremia as well as lack of recurrent bacteremia within 90 days of
follow-up.
n/a